1Boldt A, Wetzel U, Weigl J, et al. Expression of angiotensin Ⅱ receptors in human left and fight atrial tissue in atrial fibrillation withand with out underlying mitral valve disease[J]. J Am Coll Cardiol,2003,42 : 1785-1792.
2Kim NH, Ahn Y, Oh SK, et al. Altered patterns of gene expression in response to chronic atrial fibrillation [ J ].Int Heart J, 2005,46:383-395.
3Cardin S, Li D, Thorin-Trescases N, et al. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways [ J ]. Cardiovasc Res, 2003,60:315-325.
4Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin Ⅱ type 1 receptor antagonist on electrical and structural remodehng in atrial frbrillation[J] .J Am Coll Cardiol,2003,41:2197-2204.
5Gassanov N, Brandt MC, Michels G, et al. Angiotensin Ⅱ-induced changes of calcium sparks and ionic currents in human atrial myocytes: Potential role for early remodeling in atrial frbrillation[J]. Cell Calcium, 2006,39 : 175-186.
6Chen Y J, Chen YC, Tai CT, et al. Angiotensin Ⅱ and angiotensin Ⅱ receptor blocker modulate the arrhythmogenic activity of pulmonary veins [ J ]. Br J Pharmacol, 2006, 147 : 12-22.
7Shi Y, Li D, Tardif JC, et al. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure[J].Cardiovasc Res, 2002,54:456-161.
8Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction [J]. Circulation, 1999, 100:376-380.
9Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT) [ J ]. Am Heart J,2005,149:548-557.
10L' Allier PL, Ducharme A, Keller PF, et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation [ J ].J Am Coll Cardiol,2004,44:159-164.
